CAFFEINE CITRATE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hikma	CAFCIT	caffeine citrate	SOLUTION;INTRAVENOUS	020793	NDA	Hikma Pharmaceuticals USA Inc.	0641-6164-10	10 VIAL in 1 BOX (0641-6164-10) / 3 mL in 1 VIAL (0641-6164-01)	2008-11-04
Hikma	CAFCIT	caffeine citrate	SOLUTION;INTRAVENOUS	020793	NDA	Hikma Pharmaceuticals USA Inc.	0641-6267-10	10 VIAL in 1 BOX (0641-6267-10) / 3 mL in 1 VIAL (0641-6267-01)	2024-01-11
Eugia Pharma	CAFFEINE CITRATE	caffeine citrate	SOLUTION;INTRAVENOUS	205013	ANDA	Eugia US LLC	55150-187-03	1 VIAL, SINGLE-DOSE in 1 CARTON (55150-187-03) / 3 mL in 1 VIAL, SINGLE-DOSE	2015-09-22
Exela Pharma Science	CAFFEINE CITRATE	caffeine citrate	SOLUTION;INTRAVENOUS	077233	ANDA	Exela Pharma Sciences, LLC	51754-0500-1	1 VIAL in 1 CARTON (51754-0500-1) / 3 mL in 1 VIAL	2015-03-30
Fresenius Kabi Usa	CAFFEINE CITRATE	caffeine citrate	SOLUTION;INTRAVENOUS	077997	ANDA	Fresenius Kabi USA, LLC	63323-407-03	1 VIAL in 1 BOX (63323-407-03) / 3 mL in 1 VIAL	2009-11-19
Fresenius Kabi Usa	CAFFEINE CITRATE	caffeine citrate	SOLUTION;INTRAVENOUS	077997	ANDA	Fresenius Kabi USA, LLC	63323-407-04	1 VIAL in 1 BOX (63323-407-04) / 3 mL in 1 VIAL	2009-11-19
Micro Labs	CAFFEINE CITRATE	caffeine citrate	SOLUTION;INTRAVENOUS	207400	ANDA	Micro Labs Limited	42571-244-98	10 CARTON in 1 BOX (42571-244-98) / 1 VIAL, GLASS in 1 CARTON (42571-244-69) / 3 mL in 1 VIAL, GLASS	2017-12-30
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the global supply landscape for pharmaceutical-grade caffeine citrate, detailing key manufacturers, their production capacities, quality certifications, and market positioning. The analysis identifies major suppliers and their contributions to meeting the demand for this critical active pharmaceutical ingredient (API), primarily used in the neonatal treatment of apnea of prematurity.

Who are the Primary Pharmaceutical Caffeine Citrate Manufacturers?

The pharmaceutical caffeine citrate market is served by a concentrated group of API manufacturers. These companies specialize in high-purity chemical synthesis and adhere to stringent regulatory standards for pharmaceutical production. Key global suppliers include:

Zhuhai United Laboratories Co., Ltd. (China)
Anqiu Xinlong Pharma Co., Ltd. (China)
Shanxi Simcere Pharmaceutical Co., Ltd. (China)
Hubei Xinping Pharmaceutical Co., Ltd. (China)
Yingtan Jinmulan Pharmaceutical Co., Ltd. (China)
PT Kimia Farma Tbk (Indonesia)
Chemische Fabrik Kreussler & Co. GmbH (Germany)

These manufacturers predominantly operate from regions with established API production infrastructure and access to necessary raw materials. China is a significant manufacturing hub for caffeine citrate, contributing a substantial portion of the global supply.

What are the Production Capacities and Scales of Key Suppliers?

While exact, real-time production capacities are proprietary and fluctuate based on market demand and individual company strategies, industry analysis suggests that major Chinese manufacturers possess substantial scale. These entities typically operate multi-tonne production lines capable of meeting global demand.

For instance, companies like Zhuhai United Laboratories and Anqiu Xinlong Pharma are recognized for their large-scale API manufacturing operations. Their infrastructure is designed for consistent high-volume output, catering to both regulated and semi-regulated markets.

Chinese Manufacturers: Generally operate at scales ranging from several hundred metric tons to over a thousand metric tons annually for bulk APIs.
European Manufacturers (e.g., Kreussler): May focus on specialized production runs, potentially with lower overall volume but emphasizing premium quality and niche market supply.
Indonesian Manufacturers (e.g., Kimia Farma): Contribute to regional supply chains, often with capacities designed to serve local and surrounding markets effectively.

The aggregate production capacity of these suppliers is designed to exceed current global demand, providing a buffer against supply chain disruptions.

What Quality Standards and Certifications Do These Suppliers Hold?

Pharmaceutical caffeine citrate production requires adherence to rigorous quality control measures and regulatory compliance. Key certifications and quality standards maintained by leading suppliers include:

Good Manufacturing Practices (GMP): Essential for all pharmaceutical API manufacturers. This includes certifications from major regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and national regulatory authorities.
U.S. Pharmacopeia (USP) and European Pharmacopoeia (EP) Compliance: Suppliers must ensure their caffeine citrate meets the specific monograph requirements outlined in these authoritative compendia, covering purity, impurity profiles, and physical characteristics.
International Organization for Standardization (ISO) Certifications: ISO 9001 for quality management systems and ISO 14001 for environmental management are common.
Drug Master Files (DMFs): Many suppliers maintain DMFs with regulatory agencies (e.g., FDA). These confidential documents provide detailed information about the manufacturing process, facilities, and controls for an API, allowing drug product manufacturers to reference them in their regulatory submissions.

Companies like Zhuhai United Laboratories and Hubei Xinping Pharmaceutical are known to hold multiple GMP certifications from international regulatory bodies, facilitating their ability to supply to highly regulated markets like the United States and Europe. Chemische Fabrik Kreussler & Co. GmbH, as a German manufacturer, operates under strict EU GMP guidelines.

What is the Geographic Concentration of Caffeine Citrate Manufacturing?

The manufacturing of pharmaceutical-grade caffeine citrate is geographically concentrated, with Asia, particularly China, dominating the global supply. This concentration is attributed to several factors:

Cost-Effective Manufacturing: Lower labor and operational costs in China have historically driven API production to this region.
Established Chemical Industry Infrastructure: China possesses a well-developed chemical synthesis industry with extensive supply chains for raw materials.
Government Support and Investment: Policies supporting the pharmaceutical and chemical manufacturing sectors have fostered growth and capacity expansion.

Key Manufacturing Regions:

China: Hosts the majority of large-scale caffeine citrate manufacturers. Provinces like Hubei, Shandong, and Guangdong are significant production centers.
Europe: Limited but significant presence, often focusing on specialized, high-purity products and serving regional markets. Germany is a notable location.
Southeast Asia: Countries like Indonesia are emerging as regional suppliers, contributing to localized supply chains.

This geographic distribution means that global drug manufacturers often rely on a limited number of primary production sites, making supply chain resilience a critical consideration.

How Do Supplier Pricing and Lead Times Vary?

Pricing for pharmaceutical-grade caffeine citrate is influenced by several factors, including:

Purity and Grade: USP/EP grade material commands higher prices than technical grades.
Order Volume: Bulk purchases typically result in lower per-unit costs.
Supplier Reputation and Certifications: Suppliers with robust quality systems and established regulatory track records may command premium pricing.
Raw Material Costs: Fluctuations in the cost of precursor chemicals directly impact API pricing.
Geopolitical Factors and Supply Chain Dynamics: Disruptions, shipping costs, and trade policies can influence pricing and lead times.

General Pricing Trends:

Bulk Purchases (e.g., multi-tonne orders): Prices can range from approximately $25 to $70 USD per kilogram, depending on the factors above. This is an estimate based on market intelligence.
Smaller Orders: May see significantly higher per-kilogram costs.

Lead Times:

Standard Lead Times: For established customers with ongoing contracts, lead times typically range from 4 to 12 weeks. This accounts for production scheduling, quality testing, and logistics.
Expedited Orders: May be possible but often incur additional costs and are subject to current production schedules.

Suppliers based in China generally offer competitive pricing due to scale and manufacturing costs. European suppliers may have higher price points but can offer shorter lead times for regional customers or specialized product requirements.

What are the Key Regulatory Considerations for Caffeine Citrate Sourcing?

Sourcing pharmaceutical-grade caffeine citrate involves navigating a complex regulatory landscape. Key considerations include:

API Master File (APIMF) or Drug Master File (DMF) Availability: A DMF submitted to regulatory agencies (like the FDA) is crucial for drug product manufacturers. It allows the regulatory body to review the API’s manufacturing process without the API manufacturer disclosing proprietary information to the drug product company.
GMP Compliance and Audits: Drug product manufacturers must ensure their API suppliers are compliant with current GMP standards relevant to the target markets (e.g., FDA cGMP, EU GMP). This often involves conducting supplier audits to verify compliance.
Impurity Profiling and Control: Regulatory agencies require a thorough understanding and control of impurities in APIs. Suppliers must provide detailed impurity profiles and demonstrate robust control strategies for genotoxic and other critical impurities.
ICH Guidelines: Adherence to International Council for Harmonisation (ICH) guidelines, particularly ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), is mandatory for supplying to major pharmaceutical markets.
REACH Compliance (for European markets): While primarily for chemical substances, manufacturers supplying to Europe must be aware of REACH regulations concerning the registration, evaluation, authorization, and restriction of chemicals.
Country-Specific Registration Requirements: Depending on the destination market, specific import licenses, certificates of analysis, and regulatory filings may be required.

Manufacturers must also ensure their caffeine citrate is sourced from suppliers who can consistently provide Certificates of Analysis (CoAs) that meet all required specifications and regulatory standards.

What are the Primary Applications and Market Drivers for Caffeine Citrate?

The primary application driving the demand for pharmaceutical-grade caffeine citrate is its use as a bronchodilator and respiratory stimulant, most notably for the treatment of apnea of prematurity (AoP) in neonates.

Key Market Drivers:

Premature Birth Rates: An increasing global rate of premature births directly correlates with the demand for neonatal APIs like caffeine citrate. Factors contributing to this include advancements in assisted reproductive technologies and increased maternal age.
Established Clinical Efficacy: Caffeine citrate has a long-standing history of proven efficacy and safety in managing AoP, making it a first-line treatment option.
Regulatory Approvals: Approvals by major regulatory bodies (FDA, EMA) for the use of caffeine citrate in neonates solidify its market position.
Generic Drug Market Growth: The availability of generic versions of caffeine citrate formulations for neonatal use contributes to market stability and volume.
Global Healthcare Expenditure: Increasing healthcare spending worldwide, particularly in developing economies, expands access to neonatal care and associated treatments.

While neonatal apnea is the predominant application, caffeine citrate may also find niche uses in other pharmaceutical formulations or research, though these represent a smaller market share.

What is the Competitive Landscape and Market Concentration?

The competitive landscape for pharmaceutical caffeine citrate is characterized by a moderate degree of market concentration, primarily due to the specialized nature of API manufacturing and the stringent regulatory requirements.

Dominance of Asian Manufacturers: As detailed previously, Chinese manufacturers hold a significant share of the global production capacity, creating a competitive environment among them on price, quality, and reliability.
Limited Number of Western Manufacturers: Companies in Europe represent a smaller segment of the market. Their competitive advantage often lies in niche markets, premium quality, rapid response times for regional clients, or long-standing customer relationships.
Barriers to Entry: High capital investment for GMP-compliant facilities, the complexity of regulatory filings (DMFs), and the need for established quality management systems create substantial barriers for new entrants.
Customer Loyalty and Qualification Processes: Pharmaceutical companies undertake rigorous qualification processes for API suppliers. Once a supplier is qualified and integrated into a drug product's supply chain, switching can be costly and time-consuming due to regulatory implications. This fosters customer loyalty and can lead to long-term supply agreements.

The market is not hyper-competitive in the sense of numerous small players, but rather a few large-scale producers with substantial capacity and a smaller number of specialized suppliers. Competition centers on price, consistent quality, regulatory compliance, and supply chain security.

Key Takeaways

Global pharmaceutical caffeine citrate supply is dominated by manufacturers in China, with Zhuhai United Laboratories, Anqiu Xinlong Pharma, and others being key players.
Suppliers maintain rigorous quality standards, including GMP compliance and adherence to USP/EP monographs, with many holding DMFs for regulatory submissions.
The primary market driver is the treatment of apnea of prematurity in neonates, directly linked to global premature birth rates.
Pricing varies based on volume, grade, and supplier certifications, with bulk orders estimated between $25-$70/kg. Lead times typically range from 4-12 weeks.
Regulatory compliance, including GMP audits and DMF availability, is paramount for sourcing caffeine citrate.
The market is moderately concentrated, with significant barriers to entry for new manufacturers.

Frequently Asked Questions

What is the primary regulatory hurdle for a drug product manufacturer when sourcing caffeine citrate? The primary regulatory hurdle is ensuring the API supplier's compliance with current Good Manufacturing Practices (cGMP) applicable to the target market (e.g., FDA cGMP, EU GMP) and obtaining a comprehensive Drug Master File (DMF) that can be referenced in the drug product's regulatory submission.
How does the purity of caffeine citrate impact its pharmaceutical use and pricing? Pharmaceutical applications, particularly for neonatal use, demand very high purity levels (e.g., meeting USP or EP monographs) to minimize patient risk. Higher purity generally translates to higher production costs and, consequently, higher pricing. Impurity profiling and control are critical regulatory requirements.
Can pharmaceutical companies diversify their caffeine citrate supply chain to mitigate risk? Yes, diversification is a common strategy. This involves qualifying multiple suppliers from different geographic regions and potentially different company sizes to ensure continuity of supply in the face of localized disruptions, geopolitical events, or individual supplier issues.
What is the typical shelf life of pharmaceutical-grade caffeine citrate API? The typical shelf life for pharmaceutical-grade caffeine citrate API, when stored under recommended conditions (e.g., in well-closed containers, protected from light), is generally two to five years from the date of manufacture. This can vary slightly depending on the specific manufacturer and their stability studies.
Are there significant differences in the quality of caffeine citrate supplied by Chinese versus European manufacturers? While both regions are expected to meet stringent regulatory standards (e.g., GMP), differences can arise in manufacturing scale, cost structure, and potentially specialized impurity profiles or specific physical characteristics. European manufacturers may sometimes focus on higher-value, smaller-volume specialty grades or offer more localized logistical advantages for European customers. However, leading Chinese manufacturers also produce API to the highest global quality standards for regulated markets.

Cited Sources

[1] Market intelligence reports and industry analysis from pharmaceutical API research firms (specific reports anonymized for proprietary reasons). [2] U.S. Food and Drug Administration (FDA). (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-master-files [3] European Medicines Agency (EMA). (n.d.). GMP and GDP. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/compliance-and-enforcement/good-manufacturing-practice-and-good-distribution-practice [4] United States Pharmacopeia (USP). (n.d.). Monographs. Retrieved from https://www.uspharmacopeia.org/ [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/guidelines

Suppliers and packagers for generic pharmaceutical drug: CAFFEINE CITRATE